The global nicotine transdermal patches market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). A nicotine patch is a medicine that helps people to quit smoking by slowly releasing small amounts of nicotine to curb cravings. They act as a replacement for cigarettes, cigars, and other nicotine-containing products. The major factor driving the demand for the global nicotine transdermal patches market during the forecast period is the increasing research and development coupled with the rising awareness regarding smoking health issues among the population across the globe.
Moreover, the market is also growing due to the rising awareness regarding the benefits of using nicotine patches. Furthermore, the rising government initiatives and activities to reduce smoking is driving the growth of the market. For instance, in July 2020, WHO together with the UN Interagency Task Force on Non-communicable Diseases, PATH, and the Coalition for Access to NCD Medicines and Products announced a new Access Initiative for Quitting Tobacco. It aims to help the 1.3 billion tobacco users globally to quit by providing free access to nicotine replacement therapy and to Florence, a digital health worker, based on artificial intelligence that dispels myths around COVID-19 and tobacco and helps people develop a personalized plan to quit tobacco.
Browse the full report description “Global Nicotine Transdermal Patches Market Size, Share & Trends Analysis Report, By Type (21mg/patch, 14mg/patch, and 7mg/patch), By Application (Age below 30, Age 30-50, Age above 50), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/nicotine-transdermal-patches-market
Some of the key players in the market include Cigna Corp., Dr Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., and Novartis International AG, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2021, Johnson & Johnson announced that it has donated nicotine replacement therapy worth $ 800,000 through its partnership with the Access Initiative for Quitting Tobacco (AIQT) to the Ministry of Health of Jordan. The donation was aimed to support thousands of Jordanians and refugees quit smoking during the COVID-19 pandemic and after.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Cigna Corp., Dr Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novartis International AG, and others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Nicotine Transdermal Patches Market Report Segment
By Type
By Application
Global Nicotine Transdermal Patches Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World